Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment for inflammatory bowel disease: clinical trial experience
- Vedolizumab (VDZ) is a humanised monoclonal antibody that binds to α4β7 integrin and selectively blocks gut-specific lymphocyte trafficking. Although upper respiratory tract infections (URTIs) have been reported with VDZ  its gut selectivity may reduce the risk of respiratory tract infections (RTIs), including pneumonia, compared with therapies producing systemic immunosuppression (e.g. anti-tumour necrosis factor-alpha [TNFα] agents). We aimed to determine the incidence of RTIs associated with VDZ treatment in the clinical trial setting.
- Publication status:
- Peer review status:
- Peer reviewed
(Accepted manuscript, pdf, 219.3KB)
- Publisher copy:
- Pubs id:
- Local pid:
- Deposit date:
- Copyright holder:
- European Crohn’s and Colitis Organisation
- Copyright date:
- © 2017 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. This is the accepted manuscript version of the article. The final version is available online from OUP at: 10.1093/ecco-jcc/jjx002.567. This poster was presented at the 12th Congress of ECCO (February 15-18, 2017: Barcelona, Spain).